Company intelligence / Profile preview

Arsanis

Waltham, Massachusetts, United Statesinvestors.x4pharma.com ↗

Ownership: Private
Employees: ~34
Development stage: Phase 3

Overview

Arsanis developed targeted monoclonal antibody therapies for severe infectious diseases, focusing on antibiotic-resistant pathogens. Its lead program ASN100 targeted S. aureus and advanced to Phase II clinical trials but was discontinued after not meeting endpoints. The company built a broad pipeline against multiple bacterial threats using proprietary mAb discovery technology before merging with X4 Pharmaceuticals in March 2019.[2][3][4]

Therapeutic areas: Infectious Diseases
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

X4P-001

Phase 3

Indications: WHIM syndrome, Melanoma, Renal cell carcinoma

Partnerships

Adimab (antibody discovery partner)pharmaceutical collaborations for R&D funding [1][5]

Beyond the preview

Go deeper on Arsanis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arsanis.

Explore the full profile